

FOR RELEASE:

Vybion Awarded Monoclonal Antibody Development Contract

Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes, developing the expression lines and the process for manufacturing the product. The antibody, specific for cocaine, binds cocaine in the blood stream, causing cocaine in brain tissues to cross the blood brain barrier back into the blood where it remains bound to the antibody prior to detoxification in liver.

For further information please contact:

Lee A. Henderson, Ph.D.
President & CEO
lhenderson@vybion.com
607-266-0860 ext 223

John D. Noti, Ph.D.
Director, Research & Development
jnoti@vybion.com
607-266-0860 ext 224

Vybion, Inc.
33 Thornwood Dr.
Ithaca, NY 14850

About Vybion, Inc.

Vybion is an early stage developer of recombinant proteins for biopharmaceuticals and diagnostics. Vybion's ProCode™ platform rapidly selects and affinity matures human monoclonal antibodies and optimizes solubility. The Company has developed over 100 proteins, has proprietary technologies in the areas of drug discovery, development and gene expression and is experienced in optimization of gene expression, fermentation, upstream and downstream process development and scale up for clinical manufacturing. Vybion technologies are a result of over 10 years of collaborative and internal research.